Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03401918 · ClinicalTrials.gov registry record · Phase 2

Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility

A Phase 2 study, sponsored by Stanford University.

Completed
Registry status
Phase 2
Development phase
41
Enrollment target

NCT03401918: Completed Phase 2 study, sponsored by Stanford University.

NCT03401918 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03401918, a Phase 2 study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 2
Development phase
41 participants
Enrollment target

Study Summary

The purpose of this study is to determine if patients with recurrent pregnancy loss or unexplained infertility have an altered uterine gene expression or uterine microbiome (micro-organism composition) during the window of embryo implantation. Furthermore we would like to assess for women with an abnormal uterine gene expression whether vaginal progesterone medication improves or alters gene expression and for women with an abnormal microbiome whether antibiotic treatment followed by probiotic treatment normalizes the microbiome.

Primary Outcome

The primary outcome will abnormal microbiome results. An abnormal microbiome will be defined as less then 90% lactobacilli on DNA sequencing

Interventions

  • DIAGNOSTIC_TEST Uterine ERA and microbiome testing
  • DRUG Oral antibiotics and vaginal probiotics

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2017-08-01
Est. Completion 2021-07-01
Phase Phase 2
Stanford University

1,744 total trials

What the finished NCT03401918 record still lists

NCT03401918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).

The record links to 0 conditions, and to 2 interventions - of which Uterine ERA and microbiome testing is the first listed.

NCT03401918 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03401918 about?

NCT03401918 is a clinical study titled "Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility". The purpose of this study is to determine if patients with recurrent pregnancy loss or unexplained infertility have an altered uterine gene expression or uterine microbiome (micro-organism composition) during the window of embryo implantation. Furthermore we would like to assess for women with an ab...

What is the current status of trial NCT03401918?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2017-08-01. Estimated completion is 2021-07-01.

What interventions are being tested in trial NCT03401918?

The interventions under investigation include: Uterine ERA and microbiome testing (DIAGNOSTIC_TEST), Oral antibiotics and vaginal probiotics (DRUG).

Who is sponsoring clinical trial NCT03401918?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03401918's enrollment target sits among peer trials

41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03401918, the US trial registry maintained by the National Library of Medicine. NCT03401918 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.